Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | ROS1 | P08922 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14217351 | 0.94 | CYP1A1 (0.39) | CYP1A1KMT2AHTR6SUV39H2ROS1 | |
| SCHEMBL14119606 | 0.91 | SLC6A2 (0.39) | CYP1A1F10POLBSUV39H2SLC6A2 | |
| SCHEMBL2301327 | 0.85 | CYP1A1 (0.39) | CYP1A1POLBSUV39H2ROS1ALK | |
| SCHEMBL14217370 | 0.82 | CYP1A1 (0.39) | CYP1A1THRBF10POLBSLC6A2 | |
| SCHEMBL2233885 | 0.82 | ALDH1A1 (0.39) | CYP1A1THRBHTR6LMNA | |
| SCHEMBL2235517 | 0.82 | MAPT (0.42) | CYP1A1THRBKMT2AHTR6LMNA | |
| SCHEMBL14217366 | 0.80 | CYP1A1 (0.46) | CYP1A1KMT2AHTR6PTGS2 | |
| SCHEMBL14119490 | 0.80 | CYP1A1 (0.42) | CYP1A1THRBKMT2AHTR6F10 | |
| SCHEMBL2299623 | 0.78 | LMNA (0.39) | CYP1A1KMT2AHTR6LMNA | |
| SCHEMBL14238775 | 0.78 | CYP1A1 (0.37) | CYP1A1THRBF10SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | CCNY, RPS4Y1, TPX2 | CYP1A1 1777/4885THRB 1623/4885KMT2A 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.